TOPLINE:

In patients with chronic obstructive pulmonary disease (COPD), initiating a once-daily umeclidinium-vilanterol dry powder inhaler was associated with a lower risk for moderate or severe COPD exacerbations than initiating twice-daily glycopyrrolate-formoterol metered-dose inhalers or once-daily tiotropium-olodaterol soft mist inhalers.

METHODOLOGY:

• Researchers conducted an observational study using real‑world data to compare the effectiveness and safety of initiating three fixed‑dose long‑acting muscarinic antagonist (LAMA)-long‑acting beta‑2 agonist (LABA) inhalers for COPD: once‑daily umeclidinium-vilanterol (dry powder), twice‑daily glycopyrrolate formoterol (metered dose), and once‑daily tiotropium-olodaterol (soft mist).
• They assembled 55,817 propensity score-matched pairs across three separate cohorts — 9479 pairs for umeclidinium-vilanterol vs glycopyrrolate-formoterol, 9598 pairs for tiotropium-olodaterol vs glycopyrrolate-formoterol, and 36,740 pairs for umeclidinium-vilanterol vs tiotropium-olodaterol.
• Cohorts included patients aged 40 years or older who had an active COPD diagnosis and continuous health plan enrollment during the 183 days before inhaler initiation; all patients were new users of the study inhalers.
• The primary outcome was the time until the first occurrence of a moderate or severe COPD exacerbation; moderate events were defined by oral glucocorticoid prescription fills with a supply of 5-14 days, and severe events were defined by hospitalizations with a primary COPD diagnosis.
• Safety outcomes included the time to the first major adverse cardiovascular event, the first outpatient urinary tract infection, or the first pneumonia‑related hospitalization. Follow-up assessments began 1 day after the cohort entry date and continued for up to 1 year.

TAKEAWAY:

• Umeclidinium-vilanterol was associated with a 14% lower hazard of the first moderate or severe COPD exacerbation than glycopyrrolate-formoterol (hazard ratio [HR], 0.86; 95% CI, 0.81-0.91) and a modest 3% lower hazard than tiotropium-olodaterol (HR, 0.97; 95% CI, 0.94-0.99).
• Over 1 year, compared with glycopyrrolate-formoterol and tiotropium-olodaterol, umeclidinium-vilanterol was associated with 14% (95% CI, 0.81-0.91) and 8% (95% CI, 0.89-0.95) lower rates of moderate or severe exacerbations, respectively.
• No meaningful differences in safety outcomes were observed across the three therapies; risks for major cardiovascular events, outpatient urinary tract infections, and pneumonia‑related hospitalizations were similar across all cohorts.

IN PRACTICE:

“Patients, prescribers, payers, and health systems seeking to reduce greenhouse gas emissions may favor the once-daily umeclidinium-vilanterol dry powder inhaler over other LAMA-LABA inhalers for new users without compromising clinical outcomes,” the authors wrote. 

SOURCE:

The study was led by Gerard T. Portela, PhD, Brigham and Women’s Hospital, Boston. It was published online on February 23, 2026, in JAMA Internal Medicine.

LIMITATIONS:

The study used claims data from large commercial and Medicare Advantage plans; hence, the findings may not be applicable to patients with other types of coverage. It assessed only three LAMA-LABA inhalers. In addition, many patients were censored after discontinuing inhaler therapy, resulting in a relatively short follow-up period.

DISCLOSURES:

This study was funded by the National Heart, Lung, and Blood Institute. Some authors reported receiving grants, personal fees, or speaker fees; serving on advisory boards; or consulting for various companies and organizations; one author also served as an expert witness in litigation against inhaler manufacturers.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.